Murphy Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Murphy Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$969K	Sell	13,050 -290	-2%	-$21.8K	0.13%	110
2022 Q1	$1.2M	Sell	13,340 -15	-0.1%	-$1.39K	0.14%	102
2021 Q4	$1.5M	Sell	13,355 -1,000	-7%	-$121K	0.16%	97
2021 Q3	$1.8M	Buy	14,355 +65	+0.5%	+$8.37K	0.21%	90
2021 Q2	$1.93M	Sell	14,290 -330	-2%	-$43.4K	0.22%	90
2021 Q1	$1.98M	Buy	14,620 +275	+2%	+$41.2K	0.25%	87
2020 Q4	$2.02M	Sell	14,345 -300	-2%	-$38.4K	0.27%	82
2020 Q3	$1.63M	Sell	14,645 -320	-2%	-$35.9K	0.24%	88
2020 Q2	$1.68M	Buy	14,965 +250	+2%	+$24.6K	0.26%	87
2020 Q1	$1.14M	Sell	14,715 -200	-1%	-$17.7K	0.22%	99
2019 Q4	$1.42M	Sell	14,915 -780	-5%	-$67.5K	0.2%	107
2019 Q3	$1.2M	Sell	15,695 -1,005	-6%	-$83.5K	0.18%	112
2019 Q2	$1.46M	Sell	16,700 -330	-2%	-$28.1K	0.22%	107
2019 Q1	$1.54M	Sell	17,030 -890	-5%	-$75.7K	0.24%	104
2018 Q4	$1.28M	Sell	17,920 -1,425	-7%	-$115K	0.22%	107
2018 Q3	$1.85M	Sell	19,345 -700	-3%	-$67.9K	0.26%	93
2018 Q2	$1.91M	Sell	20,045 -1,000	-5%	-$91.9K	0.28%	90
2018 Q1	$1.85M	Sell	21,045 -770	-4%	-$70.3K	0.26%	96
2017 Q4	$1.85M	Sell	21,815 -1,210	-5%	-$101K	0.25%	100
2017 Q3	$1.99M	Sell	23,025 -1,400	-6%	-$112K	0.29%	91
2017 Q2	$1.89M	Buy	24,425 +100	+0.4%	+$7.09K	0.28%	91
2017 Q1	$1.69M	Hold	24,325	–	–	0.25%	99
2016 Q4	$1.44M	Sell	24,325 -1,124	-4%	-$69.4K	0.23%	105
2016 Q3	$1.69M	Sell	25,449 -746	-3%	-$46.1K	0.26%	95
2016 Q2	$1.42M	Sell	26,195 -1,775	-6%	-$97.3K	0.22%	103
2016 Q1	$1.44M	Sell	27,970 -1,975	-7%	-$103K	0.23%	104
2015 Q4	$2.1M	Sell	29,945 -2,080	-6%	-$142K	0.32%	78
2015 Q3	$1.99M	Sell	32,025 -1,485	-4%	-$117K	0.33%	83
2015 Q2	$2.82M	Sell	33,510 -975	-3%	-$75.8K	0.42%	67
2015 Q1	$2.59M	Sell	34,485 -645	-2%	-$45.1K	0.38%	74
2014 Q4	$2.18M	Sell	35,130 -720	-2%	-$41K	0.33%	84
2014 Q3	$1.86M	Sell	35,850 -3,480	-9%	-$177K	0.29%	93
2014 Q2	$2.02M	Sell	39,330 -20,970	-35%	-$945K	0.32%	87
2014 Q1	$2.86M	Sell	60,300 -45,270	-43%	-$2.32M	0.48%	61
2013 Q4	$4.58M	Sell	105,570 -285	-0.3%	-$11.8K	0.8%	35
2013 Q3	$4.56M	Sell	105,855 -150	-0.1%	-$6.08K	0.86%	30
2013 Q2	$3.68M	Buy	+106,005	New	+$3.73M	0.75%	38

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Murphy Capital Management's XBI Position: Q2 2022 in Review

Murphy Capital Management reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2.2% in Q2 2022, selling an estimated $21.8K and leaving 13,050 shares worth $969K. The position accounts for 0.13% of the portfolio, ranked #110.

Murphy Capital Management first reported a position in XBI in Q2 2013 and has held it in 37 quarters since. The position peaked at $4.58M in Q4 2013. 706 funds tracked by Wall St. Rank hold XBI as of Q2 2022.

Murphy Capital Management held 13,050 shares of State Street SPDR S&P Biotech ETF worth $969K as of Q2 2022.
Murphy Capital Management sold 290 State Street SPDR S&P Biotech ETF shares in Q2 2022, an estimated $21.8K.
State Street SPDR S&P Biotech ETF made up 0.13% of Murphy Capital Management's portfolio in Q2 2022, its #110 holding.
Murphy Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q2 2013 and has held it in 37 quarters since.
Murphy Capital Management's State Street SPDR S&P Biotech ETF position peaked at $4.58M in Q4 2013.
706 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2022.

Based on Murphy Capital Management's 13F filing for Q2 2022, filed 13 Jul 2022.